TY - JOUR
T1 - Synthesis and biological activity of non-peptide fibrinogen receptor antagonists(I)-N-substituted-O-(4-aminoiminomethylphenylamino) carbonylmethyl-L-tyrosine methyl ester
AU - Xu, Tianlin
AU - Hua, Weiyi
AU - Ni, Peizhou
AU - Jiang, Xuntian
AU - Bi, Mengyu
AU - Pei, Yongmei
AU - Yan, Bing
PY - 1999/6/1
Y1 - 1999/6/1
N2 - AIM: To design and synthesize a class of compounds with inhibitory action upon ADP-induced platelet aggregation according to both the Arg-Gly-Asp(RGD) sequence and the non-peptide fibrinogen receptor antagonists that have been reported. METHODS: Tyrosine and 4-nitrobenzoic acid were used as the major reactants to obtain the target compounds by multi-step synthesis. Turbidometric technique was used to assess the inhibitory effects in vitro at 1 × 10-6 mol·L-1. RESULTS: Eighteen compounds of N-substituted-O-(4-aminoiminomethylphenylamino)carbonylmethyl-L-tyrosine methyl ester were synthesized, ten (Ia, f, g, i∼m, q, r) of them showed inhibitory action at the above concentrations while Ig with inhitory rate of 64% is the most potent one. CONCLUSION: All of the eighteen compounds are new compounds, and most of them showed antiaggregation action on platelet rich-plasma.
AB - AIM: To design and synthesize a class of compounds with inhibitory action upon ADP-induced platelet aggregation according to both the Arg-Gly-Asp(RGD) sequence and the non-peptide fibrinogen receptor antagonists that have been reported. METHODS: Tyrosine and 4-nitrobenzoic acid were used as the major reactants to obtain the target compounds by multi-step synthesis. Turbidometric technique was used to assess the inhibitory effects in vitro at 1 × 10-6 mol·L-1. RESULTS: Eighteen compounds of N-substituted-O-(4-aminoiminomethylphenylamino)carbonylmethyl-L-tyrosine methyl ester were synthesized, ten (Ia, f, g, i∼m, q, r) of them showed inhibitory action at the above concentrations while Ig with inhitory rate of 64% is the most potent one. CONCLUSION: All of the eighteen compounds are new compounds, and most of them showed antiaggregation action on platelet rich-plasma.
KW - Antiaggregation action
KW - Design
KW - N-substituted-O-(4-aminoiminomethylphenylamino)carbonylmethyl-L-tyrosine methyl ester
KW - Non-peptide fibrinogen receptor antagonists
KW - Synthesis
UR - http://www.scopus.com/inward/record.url?scp=0043136253&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0043136253
VL - 34
SP - 432
EP - 433
JO - Yaoxue Xuebao
JF - Yaoxue Xuebao
SN - 0513-4870
IS - 6
ER -